Back to search

University of Thessaly (UTH)

Θεραπευτική αντιμετώπιση οξείας μυελογενούς λευχαιμίας στους ηλικιωμένους: θεωρητική και κλινική προσέγγιση

Abstract

dc:description

Acute myeloid leukemia (AML) is a hematologic clonal disorder that afflicts mainly older adults, with a median age at diagnosis of 67 years. The optimal induction treatment of AML in the clinically and biologically heterogeneous group of elderly patients is not well-defined. To estimate the effect of induction regimens in older AML patients, we performed a network multiple treatments meta-analysis using complete remission (CR) as the main outcome. First, we evaluated the reporting quality of published RCTs concerning myeloid hematologic malignancies according to the CONSORT statement. The CONSORT (Consolidated Standards of Reporting Trials) statement is an evidence-based approach to improve the quality of RCTs. PubMed was searched for English-language RCTs involving patients with AML, chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS). Trials were considered eligible when participants were randomly assigned to at least two treatment arms and included patients with AML,CML or MDS. Quality of reporting was assessed using a 24–item questionnaire based on the CONSORT checklist. Reporting was assessed in one pre-CONSORT (1988-1995) and one post-CONSORT (1996-2008) period. The effect of CONSORT statement in high- and low-ranked journals, according to their impact factor, has also been evaluated. The search identified 261 eligible articles for analysis. Only 13 of the 24 items of CONSORT statement were addressed in 75% or more of the studies. Most items concerning the methodological issues were reported by fewer than 50% of the studies. Significant improvements over time were seen for items that assessed the methodological quality, while RCTs published in high-ranked journals showed better quality of reporting. Next, we systematically searched PubMed, EMBASE, and Cochrane Library until September 30, 2010, to identify all randomized controlled trials (RCTs) published in English that compared diverse induction chemotherapies in elderly AML patients. Our search strategy focused on RCTs that included AML patients >60 years, considering, however, that age stratification was varied between countries and over time and studies were not necessarily designed to compare elderly patients. Regimens were grouped a priori into 42 different types of induction treatment. Prognostic parameters (age, performance status, unfavourable cytogenetics, antecedent malignancy), AML outcomes (median disease-free, overall survival, CR, induction deaths), and myelotoxicity parameters (median duration until neutrophil recovery [>1.0x109/L], platelet recovery [>100x109/L], hospitalization duration) were evaluated for each induction type. In combining direct and indirect evidence, we calculated the odds ratio (OR) for each therapy relative to the most commonly used combination of standard-dose daunorubicin (30-60 mg/m2 for 3 days) and standard dose cytarabine (100 mg/m2 for 7-10 days) that was set as the reference induction treatment. We identified 65 RCTs (15,110 patients) that described 64 direct comparisons of induction treatments, but only 14 of them showed significant differences in CR after random effects meta-analyses. Median age of included patients was 68, 18.0 % had secondary AML, 21.1%had poor performance status, 26.7% displayed unfavorable cytogenetics, and 49.3% finally achieved CR. No significant differences were observed in the recorded induction toxicity parameters among the treatment arms. Through the network meta-analysis, the addition of all-trans retinoic acids or lomustine to the combination of idarubicin plus cytarabine showed significantly higher CR rate (OR: 1.93 [1.06 –3.49] and 1.76 [1.08 –2.88], respectively), whereas 5 other schemes showed a significantly lower CR rate than that of the reference induction. Median overall survival showed no difference between treatments (P=0.150) but was significantly increased during the last 30 years (P=0.001), presumably reflecting advances in AML management. In conclusion, further improvement of reporting is necessary to assess the validity of clinical research in the field of myeloid malignancies. Compared with the reference induction, significant differences were found for specific induction regimens, although most compared regimens appeared to have similar efficacy profiles. These results, however, should be interpreted with caution because the network was dominated by indirect comparisons. Data from large RCTs that make direct comparisons between treatments are needed to detect the optimal induction regimen for elderly AML patients.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ziogas, Dimitrios
  • Ζιώγας, Δημήτριος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/30317

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ziogas, Dimitrios; Ζιώγας, Δημήτριος. Θεραπευτική αντιμετώπιση οξείας μυελογενούς λευχαιμίας στους ηλικιωμένους: θεωρητική και κλινική προσέγγιση. University of Thessaly (UTH), 2011. http://hdl.handle.net/10442/hedi/30317